Endoscopy Operative Devices Market: as endoscopic biopsy volume keeps climbing faster than any single device innovation can claim credit for, the accessory manufacturers winning share are increasingly the ones expanding distribution reach into new geographies rather than those chasing the next incremental forceps or snare redesign, so channel expansion through acquisition is becoming as consequential a growth lever in this market as product development itself, and the operative devices category is being shaped as much by who controls direct sales access as by who holds the best-engineered biopsy jaw.

The global endoscopy operative devices market size was USD 6.76 Billion in 2025 and is expected to register a revenue CAGR of 6.5% during the forecast period. Market revenue growth is driven by factors such as sustained growth in global endoscopic biopsy volume, distribution channel expansion by the largest operative device manufacturers, and continued innovation in ERCP accessory and EUS needle design. The first driving factor is the sheer scale of global endoscopic biopsy volume, which continues to expand as colorectal cancer screening and GI diagnostic procedure rates rise worldwide. ERCP accessories account for approximately 28% of total 2025 market revenue, reflecting the breadth and complexity of the sphincterotome, basket, stent, and balloon devices required for a single ERCP procedure. The second driving factor is distribution channel expansion by the largest operative device manufacturers, who are acquiring regional distributors to extend direct sales reach into new geographic markets. The third driving factor is continued innovation in ERCP accessory and EUS needle design, which improves tissue acquisition quality and procedural efficiency for the physicians performing these procedures. These are some of the key factors driving revenue growth of the market.

A second layer of demand comes from the way a single distributor acquisition converts an operative device manufacturer's existing product catalogue into direct sales reach across an entirely new geographic market, which lets that manufacturer's full accessory portfolio reach new hospital and ASC accounts without requiring a separate product-by-product market entry effort. Because operative device purchasing in most markets still runs substantially through regional distributor relationships rather than direct manufacturer sales, acquiring an established regional distributor converts that distributor's existing hospital and ASC account relationships into a direct channel for the acquiring manufacturer's entire product catalogue at once, so distribution acquisitions compound revenue across an entire portfolio rather than a single product line. As a result, demand and revenue share are concentrating around manufacturers actively expanding distribution reach through acquisition, and the forecast tilts toward companies pursuing channel expansion alongside product innovation rather than product development alone. For instance, in April 2024, Karl Storz acquired Stopler, a distributor operating across Belgium, Luxembourg, and the Netherlands, directly extending its operative endoscopy sales reach across the Benelux region. These are some of the key factors driving revenue growth of the market.

Because many operative devices in this category, including biopsy forceps and polypectomy snares, are single-use disposables consumed on every procedure, hospitals and ASCs performing high procedure volumes face substantial and recurring per-procedure device costs that create sustained pressure to negotiate volume pricing or shift toward lower-cost alternatives.

Reimbursement bundling is a second constraint, because many GI endoscopy procedures are reimbursed under bundled payment codes that do not separately itemise every operative accessory used, which limits a facility's ability to pass through the cost of premium devices even where they offer genuine clinical advantages over standard alternatives.

Physician preference variability is a third constraint, since individual endoscopists often develop strong device preferences based on training and hands-on experience, which can slow a facility-wide standardisation effort even when a newer device demonstrates measurable clinical or economic advantages.

These factors substantially limit endoscopy operative devices market growth over the forecast period.

The clearest driver of demand is the sheer scale of global endoscopic biopsy volume, which continues to expand as colorectal cancer screening guidelines broaden and GI diagnostic procedure rates rise across both developed and emerging markets. Nearly every diagnostic and therapeutic endoscopy procedure requires at least one operative accessory, whether a biopsy forceps for tissue sampling or a snare for polyp removal, so operative device consumption tracks procedure volume growth directly and predictably. ERCP accessories account for approximately 28% of total 2025 market revenue, reflecting how a single ERCP procedure can require multiple sphincterotomes, baskets, stents, and balloons across its various therapeutic steps. The effect on the market is that operative device demand grows in close proportion to underlying procedure volume, providing a stable demand base beneath any single manufacturer's specific product innovation. These are some of the key factors driving revenue growth of the market.

The second driver is distribution channel expansion through acquisition, as the largest operative device manufacturers acquire regional distributors to extend direct sales reach into new geographic markets. Operative device purchasing in most markets still runs substantially through regional distributor relationships rather than direct manufacturer sales, so acquiring an established regional distributor converts that distributor's existing hospital and ASC relationships into a direct channel for the acquiring manufacturer's entire catalogue at once. In April 2024, Karl Storz acquired Stopler, a distributor operating across Belgium, Luxembourg, and the Netherlands, and the company continued this channel expansion strategy into 2025 with the acquisition of ANKLIN, a Swiss distributor, in January 2025. The effect on the market is that manufacturer revenue growth increasingly depends on distribution reach expansion as much as on new product introduction alone. These are some of the key factors driving revenue growth of the market.

ERCP accessories already account for approximately 28% of 2025 endoscopy operative devices market revenue. Distribution channel acquisitions, not just product innovation, are increasingly what determines which manufacturer captures that recurring per-procedure spend.

The third driver is continued innovation in ERCP accessory and EUS needle design, which improves tissue acquisition quality and procedural efficiency for the physicians using these devices. A biopsy forceps or EUS needle's tissue acquisition quality directly determines whether a procedure yields a diagnostic sample on the first attempt or requires a repeat procedure, so incremental design improvements in cutting geometry and core acquisition mechanics translate directly into fewer repeat procedures and faster diagnostic pathways. The effect on the market is that device design improvements, even incremental ones, carry direct clinical and economic value that supports premium pricing over commoditised standard alternatives. These are some of the key factors driving revenue growth of the market.

However, the endoscopy operative devices market faces severe adoption constraints from cost-containment pressure on single-use accessory pricing and reimbursement bundling that caps per-procedure device spending.

Because many operative devices in this category, including biopsy forceps and polypectomy snares, are single-use disposables consumed on every procedure, hospitals and ASCs performing high procedure volumes face substantial and recurring per-procedure device costs that create sustained pressure to negotiate volume pricing or shift toward lower-cost alternatives even where premium devices offer measurable clinical advantages.

Reimbursement bundling compounds this, because many GI endoscopy procedures are reimbursed under bundled payment codes that do not separately itemise every operative accessory used, which limits a facility's ability to pass through the cost of premium devices even where they offer genuine clinical advantages over standard alternatives.

Physician preference variability is the third constraint, since individual endoscopists often develop strong device preferences based on training and hands-on experience, which can slow a facility-wide standardisation effort even when a newer device demonstrates measurable clinical or economic advantages.

These factors substantially limit endoscopy operative devices market growth over the forecast period.

Based on device type, the global endoscopy operative devices market is segmented into biopsy forceps, polypectomy snares, ERCP accessories, EUS fine needle aspiration and biopsy needles, grasping forceps and retrieval devices, injection and marking needles, and endoscopic clips and closure devices. ERCP accessories hold the largest revenue share, because a single ERCP procedure typically requires multiple distinct devices across its diagnostic and therapeutic steps, which suits a market where procedural complexity concentrates the largest revenue category in the most device-intensive procedure type. Biopsy forceps remain the highest-volume device category by unit count given their use across nearly every diagnostic endoscopy procedure, but individually lower per-unit pricing than the multi-device ERCP accessory bundle keeps its overall revenue share below ERCP's. EUS fine needle aspiration and biopsy needles are expected to register the fastest revenue growth rate in the global endoscopy operative devices market over the forecast period, driven by expanding EUS-guided biopsy adoption, which is why needle manufacturers continue to prioritise cutting-tip and core-acquisition design improvements.

Gastrointestinal endoscopy application is expected to account for the largest revenue share in the global endoscopy operative devices market during the forecast period

Based on application, the global endoscopy operative devices market is segmented into gastrointestinal endoscopy, pulmonology and bronchoscopy, urology endoscopy, ENT endoscopy, and general surgery endoscopy. Gastrointestinal endoscopy holds the largest revenue share, because colonoscopy, gastroscopy, and ERCP procedure volume collectively dwarf other endoscopy application categories, which ties directly back to the biopsy volume growth described in the market's primary demand driver. Urology endoscopy is expected to register the fastest revenue growth rate in the global endoscopy operative devices market over the forecast period, driven by expanding minimally invasive urology procedure volume, which is why operative device manufacturers are increasingly developing urology-specific accessory lines alongside their established GI product catalogues.

Based on regional analysis, the endoscopy operative devices market in North America accounted for largest revenue share in 2025. The United States leads because the concentration of GI endoscopy procedure volume and Boston Scientific's confirmed US market leadership position in biopsy forceps, polypectomy snares, and ERCP devices sustains the largest single national market, and because Boston Scientific, Olympus, and Cook Medical all maintain their primary commercial presence in the US market. The scale of US ambulatory surgical centre GI procedure volume anchors a domestic operative device market large enough to sustain multiple competing manufacturers simultaneously. The concentration of GI endoscopy training programmes in the country also means new operative device designs are typically launched in the United States first, before expanding to other regional markets.

The market in Europe is expected to register a steady revenue growth rate over the forecast period. Germany, France, and the United Kingdom represent the three largest national markets within Europe. Karl Storz's continued distributor acquisition strategy, including its April 2024 Stopler acquisition covering Belgium, Luxembourg, and the Netherlands, and its January 2025 acquisition of Swiss distributor ANKLIN, is specifically expanding direct sales reach across the region. The result is steady rather than rapid growth, shaped more by national health system reimbursement negotiation than by underlying patient demand.

The market in Asia Pacific is expected to register a rapid revenue growth rate over the forecast period. China and Japan represent the two largest national markets within the region, driven by rising GI cancer screening volume and expanding hospital endoscopy capacity. China's rapidly expanding endoscopy procedure volume leaves considerably more room for growth than in the already device-saturated North American market.

The market in Latin America is expected to register a moderate revenue growth rate over the forecast period. Brazil and Mexico represent the two largest national markets within the region, with private hospital networks driving early adoption of premium operative devices among higher-income patients. The ongoing Iran-US sanctions and the resulting Strait of Hormuz shipping disruption have raised freight and import costs for the precision stainless steel and polymer components that Latin American device distributors depend on, an effect expected to run through 2026 and slow endoscopy operative devices adoption beyond Brazil's and Mexico's main urban centres.

The market in Middle East and Africa is expected to register a moderate revenue growth rate over the forecast period. Saudi Arabia and the UAE represent the primary commercial markets within the region. Saudi Arabia's expanding private hospital network and the UAE's regional distribution hubs represent the primary investment centres for endoscopy operative devices adoption. Saudi Arabia is the most established market on the continent, while the Gulf states outside it are still building the specialist GI endoscopy infrastructure needed to support advanced operative devices at scale.